• Pfizer Inc., of New York, said data from a Phase III study of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) met all endpoints, showing immunogenicity and establishing a safety profile in children and adolescents, ages 5 through 17.